148 related articles for article (PubMed ID: 10851530)
1. 186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts.
Kotts CE; Su FM; Leddy C; Dodd T; Scates S; Shalaby MR; Wirth CM; Giltinan D; Schroff RW; Fritzberg AR; Shepard HM; Slamon DJ; Hutchins BM
Cancer Biother Radiopharm; 1996 Apr; 11(2):133-44. PubMed ID: 10851530
[TBL] [Abstract][Full Text] [Related]
2. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
Chen KT; Lee TW; Lo JM
Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the biodistribution and the efficacy of monoclonal antibody 323/A3 labeled with either 131I or 186Re in human ovarian cancer xenografts.
Kievit E; van Gog FB; Schlüper HM; van Dongen GA; Pinedo HM; Boven E
Int J Radiat Oncol Biol Phys; 1997 Jul; 38(4):813-23. PubMed ID: 9240651
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.
Tsai SW; Sun Y; Williams LE; Raubitschek AA; Wu AM; Shively JE
Bioconjug Chem; 2000; 11(3):327-34. PubMed ID: 10821648
[TBL] [Abstract][Full Text] [Related]
5. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
6. Rhenium-186-mercaptoacetyltriglycine-labeled monoclonal antibody for radioimmunotherapy: in vitro assessment, in vivo kinetics and dosimetry in tumor-bearing nude mice.
Kinuya S; Yokoyama K; Tega H; Hiramatsu T; Konishi S; Yamamoto W; Shuke N; Aburano T; Watanabe N; Takayama T; Michigishi T; Tonami N
Jpn J Cancer Res; 1998 Aug; 89(8):870-8. PubMed ID: 9765625
[TBL] [Abstract][Full Text] [Related]
7. Tumor retention of 186Re-MAG3, 111In-DTPA and 125I labeled monoclonal antibody G250 in nude mice with renal cell carcinoma xenografts.
Steffens MG; Kranenborg MH; Boerman OC; Zegwaart-Hagemeier NE; Debruyne FM; Corstens FH; Oosterwijk E
Cancer Biother Radiopharm; 1998 Apr; 13(2):133-9. PubMed ID: 10850349
[TBL] [Abstract][Full Text] [Related]
8. Radiolabeled antibody targeting of the HER-2/neu oncoprotein.
De Santes K; Slamon D; Anderson SK; Shepard M; Fendly B; Maneval D; Press O
Cancer Res; 1992 Apr; 52(7):1916-23. PubMed ID: 1348016
[TBL] [Abstract][Full Text] [Related]
9. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth.
Sarup JC; Johnson RM; King KL; Fendly BM; Lipari MT; Napier MA; Ullrich A; Shepard HM
Growth Regul; 1991 Jun; 1(2):72-82. PubMed ID: 1688187
[TBL] [Abstract][Full Text] [Related]
10. Comparisons of the efficacy of 186Re- and 131I-labeled antibody in multicell spheroids.
Langmuir VK; Mendonca HL; Vanderheyden JL; Su FM
Int J Radiat Oncol Biol Phys; 1992; 24(1):127-32. PubMed ID: 1512148
[TBL] [Abstract][Full Text] [Related]
11. Rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: preparation and evaluation.
John E; Thakur ML; DeFulvio J; McDevitt MR; Damjanov I
J Nucl Med; 1993 Feb; 34(2):260-7. PubMed ID: 8429345
[TBL] [Abstract][Full Text] [Related]
12. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials.
Breitz HB; Weiden PL; Vanderheyden JL; Appelbaum JW; Bjorn MJ; Fer MF; Wolf SB; Ratliff BA; Seiler CA; Foisie DC
J Nucl Med; 1992 Jun; 33(6):1099-109. PubMed ID: 1597723
[TBL] [Abstract][Full Text] [Related]
13. Experimental radioimmunotherapy with 186Re-MAG3-A7 anti-colorectal cancer monoclonal antibody: comparison with 131I-counterpart.
Kinuya S; Yokoyama K; Kobayashi K; Motoishi S; Onoma K; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
Ann Nucl Med; 2001 Jun; 15(3):199-202. PubMed ID: 11545188
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.
Shepard HM; Lewis GD; Sarup JC; Fendly BM; Maneval D; Mordenti J; Figari I; Kotts CE; Palladino MA; Ullrich A
J Clin Immunol; 1991 May; 11(3):117-27. PubMed ID: 1679763
[TBL] [Abstract][Full Text] [Related]
15. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
16. The evaluation of 186Re-labeled antibodies using N2S4 chelate in vitro and in vivo using tumor-bearing nude mice.
Najafi A; Alauddin MM; Sosa A; Ma GQ; Chen DC; Epstein AL; Siegel ME
Int J Rad Appl Instrum B; 1992 Feb; 19(2):205-12. PubMed ID: 1601674
[TBL] [Abstract][Full Text] [Related]
17. 186Re-labeled monoclonal antibody E48 immunoglobulin G-mediated therapy of human head and neck squamous cell carcinoma xenografts.
Gerretsen M; Visser GW; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
Cancer Res; 1993 Aug; 53(15):3524-9. PubMed ID: 8339258
[TBL] [Abstract][Full Text] [Related]
18. High dose rhenium-186-labeling of monoclonal antibodies for clinical application: pitfalls and solutions.
van Gog FB; Visser GW; Stroomer JW; Roos JC; Snow GB; van Dongen GA
Cancer; 1997 Dec; 80(12 Suppl):2360-70. PubMed ID: 9406684
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of Rhenium-188-labeled Herceptin on prostate cancer cell growth: a possible radioimmunotherapy to prostate carcinoma.
Wang HY; Lin WY; Chen MC; Lin T; Chao CH; Hsu FN; Lin E; Huang CY; Luo TY; Lin H
Int J Radiat Biol; 2013 May; 89(5):346-55. PubMed ID: 23294030
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
Baselga J; Tripathy D; Mendelsohn J; Baughman S; Benz CC; Dantis L; Sklarin NT; Seidman AD; Hudis CA; Moore J; Rosen PP; Twaddell T; Henderson IC; Norton L
J Clin Oncol; 1996 Mar; 14(3):737-44. PubMed ID: 8622019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
